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Abstract
Fragile X syndrome (FXS) is the most common inherited cause of intellectual disability. In addition to cognitive deficits, FXS
patients exhibit hyperactivity, attention deficits, social difficulties, anxiety, and other autistic-like behaviors. FXS is caused by
an expanded CGG trinucleotide repeat in the 59 untranslated region of the Fragile X Mental Retardation (FMR1) gene leading
to epigenetic silencing and loss of expression of the Fragile X Mental Retardation protein (FMRP). Despite the known
relationship between FMR1 CGG repeat expansion and FMR1 silencing, the epigenetic modifications observed at the FMR1
locus, and the consequences of the loss of FMRP on human neurodevelopment and neuronal function remain poorly
understood. To address these limitations, we report on the generation of induced pluripotent stem cell (iPSC) lines from
multiple patients with FXS and the characterization of their differentiation into post-mitotic neurons and glia. We show that
clones from reprogrammed FXS patient fibroblast lines exhibit variation with respect to the predominant CGG-repeat length
in the FMR1 gene. In two cases, iPSC clones contained predominant CGG-repeat lengths shorter than measured in
corresponding input population of fibroblasts. In another instance, reprogramming a mosaic patient having both normal
and pre-mutation length CGG repeats resulted in genetically matched iPSC clonal lines differing in FMR1 promoter CpG
methylation and FMRP expression. Using this panel of patient-specific, FXS iPSC models, we demonstrate aberrant neuronal
differentiation from FXS iPSCs that is directly correlated with epigenetic modification of the FMR1 gene and a loss of FMRP
expression. Overall, these findings provide evidence for a key role for FMRP early in human neurodevelopment prior to
synaptogenesis and have implications for modeling of FXS using iPSC technology. By revealing disease-associated cellular
phenotypes in human neurons, these iPSC models will aid in the discovery of novel therapeutics for FXS and other autism-
spectrum disorders sharing common pathophysiology.
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Introduction
The autism spectrum disorders (ASDs) are a group of neuro-
developmental diseases caused by multiple genetic and environ-
mental factors [1]. Despite the immense etiological heterogeneity
in ASDs, affected individuals have common behavioral manifes-
tations that may arise due to perturbation of common neurode-
velopmental processes. In the long term, identification of common
cell- and molecular-level elements underlying the ASDs will
require a broad study of both idiopathic and genetically correlated
cases.
One of the major obstacles to identification of therapeutic
interventions for the ASDs has been the difficulty of studying the
step-by-step development of the disease in systems that are
amenable to drug and functional genomic screening. Recent
advances in stem cell biology and the advent of somatic cell
reprogramming technology now enable the generation of patient-
specific induced pluripotent stem cells (iPSCs) that can be
differentiated in vitro into a variety of cell types of the nervous
system. Through the use of these patient-derived cell models,
iPSCs provide a means to: i) potentially recapitulate the step-by-
step development of disease, ii) discover the underlying molecular
mechanisms involved in the disease pathology, and iii) apply
existing and emerging approaches for discovering and testing
different classes of therapeutics that target early steps in disease
pathogenesis [2].
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Of the small percentage of individuals with genetically
correlated ASD [1], mutations in the X-chromosome linked
fragile X mental retardation gene 1 (FMR1) gene in Fragile X
syndrome are the most prevalent. Clinical manifestations of the
syndrome include cognitive abnormalities ranging from mild
learning impairment to severe mental retardation which often
progressively increases with age [3,4,5,6]. Behavioral symptoms of
FXS patients are variable and may include hyperactivity,
stereotypic behavior, attention deficits, social difficulties, inappro-
priate speech, restricted interests, anxiety, and other autistic-like
behaviors [4,5,6].
Loss of the fragile X mental retardation protein (FMRP) has
been shown to be causative for the cognitive and behavioral
impairments of FXS [6]. FMRP is a cytoplasmic RNA-binding
protein [7] involved in mRNA transport from the nucleus to the
dendrites in neurons where it is known to regulate the translation
of proteins important for synaptic development and plasticity in an
activity-dependent manner [8,9]. Inactivation of the FMR1 gene
in FXS is caused by expansion of a CGG trinucleotide repeat in its
59-untranslated region (59-UTR). Normal individuals have 6-50
CGG-repeats, while carriers of premutations have 50–200 repeats
[4]. As a consequence of expansion of the CGG-repeat length in
the FMR1 gene .200, through molecular mechanisms not fully
understood [10], the 5-carbon position of cytosine nucleotides
linked by a phosphate to guanine nucleotides (CpG dinucleotides)
in the promoter and CGG-repeat regions of FMR1 become
hypermethylated, resulting in epigenetic silencing of the gene and
loss of FMRP expression. In this manner, FXS can be considered
to be an epigenetic disorder and there is growing evidence that the
epigenetic state of the FMR1 gene, rather than the CGG-repeat
length itself, is the key determinant of FXS pathogenesis and also
treatment response [11,12,13,14].
We report here the development and characterization of iPSC
lines from multiple FXS-affected individuals. FXS iPSCs differed
from non-diseased control lines in expression and methylation of
the FMR1 gene and phenotypic capacity for in vitro neural
differentiation. Reprogramming of FXS, but not control
fibroblasts, demonstrated an instability of the CGG trinucleotide
stretch in the 59 UTR of the FMR1 gene. In two cases, we
observed that some of the FXS iPSC clones had repeat lengths
that were shorter than their corresponding input fibroblasts. In
one instance, we produced multiple iPSC clones from a mosaic
individual having both normal and pre-mutation length CGG
repeats, generating a set of genetically matched iPSC lines
differing in their CGG repeat lengths, FMR1 methylation and in-
vitro neural differentiation characteristics. The well-character-
ized collection of FXS pluripotent stem cells generated in this
study will be useful for understanding the mechanisms under-




Fibroblasts from three clinically diagnosed Fragile X Syndrome
male patients (GM05848, GM05131 and GM05185) and one
unrelated, unaffected male (GM08330) were purchased from
Coriell Institute for Medical Research. Fibroblasts from one
clinically unaffected male (BJ1-hFib) were also obtained from
ATCC. Cells were grown in flasks coated with 0.1% gelatin (EMD
Millipore), and grown in fibroblast media: 10% heat-inactivated
FBS (Gemini Bio-Products), 1% Penicillin/Streptomycin (Invitro-
gen), 1% non-essential amino acids (Invitrogen) and 88% DMEM
(Invitrogen) filtered through a 0.22 mm bottle-top filter.
Fibroblast Reprogramming
Retroviruses were generated by tripartite transient transfection
of pIK-MLV (gag.pol), pHDM-G (VSV), and the specific pMIG
vectors carrying the hOCT4, hSOX2, hKLF4 or hc-MYC genes)
into 293T cells as previously described [15,16]. Fibroblasts were
plated in single wells of 6-well plates at 105 cells per well. These
cells were then transduced for 24 hours with the four retroviruses
with an multiplicity of infection (MOI) of 10 for pMIG-hOCT4-
IRES-GFP (Addgene), pMIG-hSOX2-IRES-GFP (Addgene) and
pMIG-hKLF4-GFP (Addgene) and MOI of 1 for MCSV-hc-
MYC-IRES-GFP (Addgene). After 24 hours, cells were washed
with PBS and fresh media was added, and five days later cells were
passaged onto 10 cm gelatin-coated dishes with c-irradiated
mouse embryonic fibroblasts (iMEFs) (GlobalStem). The next
day the media was changed to iPSC media: 20% Knock-out
Serum Replacement ((KOSR), Invitrogen), 1% penicillin/strepto-
mycin (Invitrogen), 1% non-essential amino acids (Invitrogen),
0.5% L-glutamine (Invitrogen), 100 mM 2-mercaptoethanol (Bio-
Rad) and 77.5% DMEM/F-12 (Invitrogen) and 10 ng/mL bFGF
(Stemgent) filtered through a 0.22 mm filter (EMD Millipore).
Dishes had daily media changes until colonies emerged, (3 to 6
weeks after transduction). Colonies were first assessed based on
morphology, then for silencing of the retroviral vectors (GFP
minus) before being mechanically passaged onto gelatin coated 6-
well plates with c-irradiated mouse embryonic fibroblasts
(GlobalStem) as feeders. Using these methods, multiple clones
from each line (except GM05185 that produced only one
acceptable clone) were chosen for expansion, cryopreservation,
and further characterization.
iPSC Expansion
Reprogrammed colonies were picked into separate wells and
grown as separate clones after that point. The first several passages
were grown directly on a feeder layer of iMEFs (GlobalStem). For
removal of MEFs for downstream RT-PCR and embryoid body
formation, iPSCs were grown by indirect co-culture with iMEFs
(GlobalStem) on 1:30 Matrigel (BD Biosciences) coated polyeth-
ylene terephthalate (PET) inserts with 1.0 mm pore-size in 6-well
plates in iPSC media [17,18].
Immunocytochemistry
iPSC colonies grown on iMEFs on Permanox Lab-Tek chamber
slides (Nunc) were fixed with 10% cold methanol or 4%
paraformaldehyde in PBS for 10 minutes. Methanol fixed slides
were blocked for 1 hour in PBS plus 5% bovine serum albumin
then stained with OCT3/4 (Santa Cruz sc-101534) or NANOG
(Abcam ab21624) for 1 hour at room temperature. Paraformal-
dehyde fixed slides were blocked and then stained with SSEA4
(EMD Millipore MAB4304) or Tra-1–60 (EMD Millipore
MAB4360) 1 hour at room temperature. All slides where then
rinsed several times with PBS and slides where then incubated at
room temperature in appropriate buffer with secondary antibody
and Hoechst-33342 for 1 hour at room temperature. After several
more rinses, coverslips were affixed with Vectashield (Vector
Laboratories) and imaged with a Zeiss Axiovert microscope and
10X objective equipped with a Zeiss Axiocam digital camera.
In Vitro Differentiation of Embryoid Bodies
To form embryoid bodies, iPSC colonies grown by indirect co-
culture were broken up and grown in ultra-low attachment 6-well
plates (Corning) in iPSC media without bFGF Stemgent and 1%
heat-inactivated FBS (Gemini Bio-Products) for a minimum of 19
days. Embryoid bodies were fixed in PBS with 4% paraformal-
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dehyde for 20 minutes and pelleted in low-melt agarose, followed
by paraffin embedding and sectioning into 5 mm sections. The
sections were mounted on slides and stained with hematoxylin and
eosin for morphological examination using an Olympus BX51
microscope with a 40X objective and an Olympus Q Color 5
CCD camera [17].
Pluripotency Gene Expression Analysis
Cells collected from colonies grown by indirect co-culture were
lysed in Trizol (Invitrogen), then mixed with 1/5th volume of
chloroform and centrifuged at 200 x g for 5 minutes. The aqueous
phase was collected and processed using an RNeasy Mini column
(Qiagen) following the Animal Cells protocol. RNA was
quantitated by Nanodrop, normalized to 50 ng/mL and reverse
transcribed using Qiagen OneStep RT-PCR Kit. Primers for
endogenous pluripotency-associated genes were as described [19]:
OCT4/POU5F1 (59 primer – CTCACCCTGGGGGTTCTATT,
39 primer – CTCCAGGTTGCCTCTCACTC, 65uC annealing)
with a 230 bp product, REX1 (59 primer – TCACAGTCCAG-
CAGGTGTTTG, 39 primer – TCTTGTCTTTGCCCGTTT-
CT, 61uC annealing) with a 205 bp product, NANOG (59 primer –
CATGAGTGTGGATCCAGCTTG, 39 primer – CCTGAATA-
AGCAGATCCATGG, 64uC annealing) with a 192 bp product,
and GAPDH (59 primer – AGCCACATCGCTCAGACACC, 39
primer – GTACTCAGCGGCCAGCATCG, 62uC annealing) with
a 302 bp product as a positive control. RT-PCR primers used for
transgene analysis were as described [16]: Trans-OCT4/POU5F1 (59
primer - CCTCACTTCACTGCACTGTA, 39 primer - CCTTG-
AGGTACCAGAGATCT), Trans-SOX2 (59 primer - CCCAGCA-
GACTTCACATGT, 39 primer - CCTTGAGGTACCAGAGAT-
CT), Trans-KLF4 (59 primer - GATGAACTGACCAGGCACTA,
39 primer - CTTGAGGTACCAGAGATCT), Trans-c-MYC (59
primer - TGCCTCAAATTGGACTTTGG, 39 primer - CGCT-
CGAGGTTAACGAATT) all with a 62uC annealing, and using
respective vector plasmids as positive control for each.
Karyotype Analysis
Karyotype analysis was performed by Cell Line Genetics
(http://www.clgenetics.com) as previously described [20].
Neural Differentiation of iPSC Clones
Neural differentiation was initiated from iPSC clones grown
under feeder-free conditions to remove iMEFs either by growth
directly on Matrigel (BD Biosciences) in mTeSR1 culture medium
(StemCell Technologies) or by indirect co-culture with condition-
ing feeder layers in KOSR medium (Invitrogen) on Matrigel (BD
Biosciences) coated 1 mm porosity membrane inserts [17,18].
Expandable neuronal progenitors were isolated by one of two
ways: 1) directly by manual collection of neural rosette structures
in mTeSR1 culture media (StemCell Technologies) upon initiation
of differentiation by overgrowth of the iPSC colonies; and/or 2)
through magnetic-activated cell sorting (MACS) using microbeads
conjugated with antibodies to the polysilated form of neural cell
adhesion molecule (PSA-NCAM; Miltenyi Biotech). Isolated cells
were expanded in neural expansion medium (70% DMEM
(Invitrogen), 30% Ham’s F-12 (Mediatech) supplemented with
B-27 (Invitrogen), 20 ng/ml each EGF (Sigma) and bFGF(R&D
Systems) on poly-ornithine (Sigma)/laminin (Sigma) coated culture
plates. After five passages in expansion medium, cells were
analyzed for NESTIN and SOX1 expression by fixation in 4%
paraformaldehyde, followed by primary incubation with rabbit
anti-NESTIN polyclonal antibodies (EMD Millipore AB5922)
or mouse anti-SOX1 monoclonal antibodies (EMD Millipore
AB15766) and subsequent appropriate fluorochrome conjugated
secondary antibody for microscopic evaluation. Terminal neural
differentiation was achieved by plating expanded cells plated at a
seeding density of 40,000 cells per cm2 on polyornthine/laminin
plates as above in expansion medium lacking both EGF and
bFGF, with medium replacement every 3–5 days until the
indicated endpoint time. Two wells (6-well plate) were imaged
on an IX-Micro automated microscope (Molecular Devices), and 9
images per well were taken (n= 18 images per sample). All in-focus
images were selected for analysis. Images were thresholded to a
binary image, skeletonized, and then total pixels were counted to
determine total process length in each image using ImageJ (http://
rsbweb.nih.gov/ij).
FMR1 Transcript Quantitative RT-PCR
Cells collected from colonies grown by indirect co-culture were
lysed in Trizol (Invitrogen) then mixed with 1/5th volume of
chloroform and centrifuged at 200 x g for 5 minutes. The aqueous
phase was collected and processed using an RNeasy Mini column
(Qiagen) and the Animal Cells protocol was followed from Step 4.
RNA was quantitated by Nanodrop, normalized to 50 ng/mL, and
reverse transcribed by Clontech Reverse Transcription Kit
(Clontech) according to manufacturer’s instructions. Samples were
then run on a Roche LightCycler 480 thermocycler using Roche
SYBR Green (Roche Diagnostics) in triplicate in 384-well plates.
PCR primers were: FMR1 (59primer - CAGGGCTGAAGAGAA-
GATGG, 39primer – ACAGGAGGTGGGAATCTGA) with a
174 bp product and RPL13A (59 primer – ACCCTGGAGGA-
GAGAGGAA, 39 primer – AGGCAACGCATGAGGAATTA)
with a 186 bp product. Transcript levels were then averaged
before being normalized using RPL13A levels. Fold-change in
transcript levels were determined by comparing transcript levels to
those from healthy control cells with these values set to 1.
FMR1 CGG-Repeat Length Analysis
DNA was extracted from live cells using Qiagen DNeasy Blood
& Tissue Kit (Qiagen). Isolated DNA was analyzed by Genzyme
Genetics (http://www.genzymegenetics.com) using both Southern
blot analysis and polymerase chain reaction (PCR) to determine
the CGG-repeat length and methylation status of the promoter
region of the FMR1 gene. Southern blot analysis was performed
with a 32P-labelled probe StB 12.3 on EcoRI and EagI digested
DNA [21]. PCR products were generated using a fluorescently
labeled primer and sized by capillary electrophoresis.
FMR1 and OCT4/POU5F1 Promoter Methylation Analysis
Bisulfite treatment of genomic DNA purified using Qiagen
DNeasy (Qiagen) and pyrosequencing analysis [22,23] of the
FMR1 and OCT4/POU5F1 promoters was performed by Epi-
genDx Inc. (http://www.epigendx.com) using the PSQTM96HS
system according to standard procedures with a unique set of
primers that were developed by EpigenDx. The human OCT4/
POU5F1 methylation assay covers ten CG dinucleotides in exon 1
region ranging from -50 to +96 from the transcriptional start site
based on Ensembl Gene ID Ensembl:ENSG00000204531 and the
Transcript ID ENST00000259915. The human FMR1 methyla-
tion assay covers twenty-two CG dinucleotides in the promoter
region ranging from -523 to -384 from the transcriptional start
site based on Ensembl Gene ID ENSG00000102081 and the
Transcript ID ENST00000370475.
Western Blotting
Cells for immunoblotting were harvested, pelleted, and frozen at
280uC. The pellets were washed three times with PBS with the
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addition of one Complete Protease Inhibitor Cocktail Tablet
(Roche Diagnostics) per 7 mL PBS. Pellets were then resuspended
in 200 mL mPER Mammalian Protein Extraction Reagent
(Thermo Scientific) with 1:100 Protease Inhibitor Cocktail III
(CalBioChem) and placed on a rocker overnight at 4uC. The
samples were centrifuged at 14,000 x g at 4uC for 15 minutes and
the supernatants were stored as 50 mL aliquots at 280uC. Protein
was quantified using a BCA assay (Thermo Scientific) read on an
Envision Plate Reader (PerkinElmer). Equal quantities of total
protein were loaded onto 4–15% Criterion pre-cast polyacryl-
amide gels (BioRad) and run at 100V for 15 minutes, then at
125V for 1.5 hours. Gels were transferred to PVDF membrane
(EMD Millipore) using standard procedures at 300 mA for 1 hour.
Membranes were rinsed in Tris-buffered saline with Tween (TBS-
T), then blocked with TBS-T + 5% powdered nonfat milk for 1
hour. Membranes were transferred to TBS-T with mouse anti-
FMRP clone 1C3 (EMD Millipore MAB2160) at room temper-
ature for 2 hours. Membranes were washed 4 times in TBS-T and
incubated for 1 hr in horseradish peroxidase-coupled secondary
antibody (Cell Signaling Technologies). Membranes were then
washed four times in TBS-T, blotted dry, incubated for 5 minutes
with SuperSignal West Pico Chemiluminescent Substrate (Thermo
Scientific), blotted dry again and exposed to BioMax MR film
(Kodak) for band visualization upon development.
Results
Characterization of Fibroblasts from Fragile X Donors:
Trinucleotide Repeat Length, CpG Methylation, FMR1
mRNA and Protein Levels
Banked fibroblast cell lines (Table 1) were obtained from three
clinically typical male FXS patients (Coriell GM05131, GM05185,
and GM05848) and two unaffected males (GM08330) and BJ1
(ATCC). As expected, all three FXS patient fibroblast lines
(GM05131, GM05185 and GM05848) had CGG repeat sizes in
the full mutation range (.200) in the FMR1 59UTR on the X
chromosome (Fig. 1A). One of the FXS cell lines, GM05131,
however, was shown to be from a mosaic donor, having two
predominant bands corresponding to 800 and 166 CGG repeats.
Mosaicism in FXS patients has been documented before, and is
estimated to occur in 20–40% of patients, possibly due to
instability of the repeat length during in utero somatic cell
development [24]. In the case of fibroblasts derived from
GM05131, the fibroblast population was a mixture of cells that
have the full mutation and cells with the permutation CGG-repeat
lengths.
Upon increasing CGG-repeat length in the FMR1 gene beyond
the normal range of 6–50, an increase in the methylation of CpG
sites in the promoter region leads to epigenetic silencing of the
gene [10,25]. To quantitatively compare the levels of methylation
within the promoter region of FMR1, bisulfite pyrosequencing was
used to query methylation status at 22 CpG sites. Both full
mutation fibroblast lines, GM05848 and GM05185 had highly
methylated promoter regions, with a mean of approximately 85%
of the CpG sites methylated, consistent with the expected
hypermethylation of this region in the FXS (Fig. 1B). In contrast,
the control BJ-1 fibroblast lines had barely detectable levels (,5%)
of CpG methylation in the same region. The mean CpG
methylation level of this region in the mosaic GM05131 fibroblast
cell line was approximately 60%, most likely because of the
presence of both cells with a hypermthylated CpG full mutation as
well as premutation fibroblasts with unmethylated FMR1 promo-
tor regions.
The combination of an expanded 59-UTR CGG trinucleotide
repeat along with the high degree of CpG site methylation of this
region would be expected to result in the silencing of the
expression of the FMR1 gene. In order to test this directly, we
performed quantitative RT-PCR analysis to assess the relative
FMR1 expression levels in the cell lines (Fig. 1C). While the control
lines expressed the FMR1 gene, the full mutation fibroblast lines
had undetectable levels of FMR1 mRNA expression. Interestingly,
the expression level of the FMR1 gene in the mosaic (premutation
plus full mutation) GM05131 line was approximately four-fold
higher than the control. This is consistent with reports that the
presence of the premutation causes an increase in gene expression
from the FMR1 promoter from two- to ten-fold over unaffected
controls [26].
FMRP protein expression in the patient fibroblasts was
determined by Western blot analysis (Fig. 1D). Whereas FMRP
was highly expressed in the unaffected control line, FMRP protein
expression was not detectable in any of the FXS patient fibroblasts.
Interestingly, the mosaic GM05131 fibroblasts that demonstrated
only partial methylation of the FMR1 promoter had undetectable
protein, even though they had elevated transcript levels; it has
been reported before that production of FMRP is greatly reduced
in the premutation state, which may be due in part to a relative
block in translation caused by the presence of the 59UTR
extended CGG repeat [27].
Derivation and Characterization of FXS Induced
Pluripotent Stem Cells
FXS patient and control fibroblasts were reprogrammed to
pluripotency using established methods (see Methods) [16,28]. We
further analyzed two iPSC clones from GM05848 (referred to as
clones 848-iPS1 and 848-iPS3), two clones from GM05131 (131-
iPS1 and 131-iPS3), one clone from GM05185 (185-iPS1) and
control iPSC lines from GM08330 (8330-iPS8) and BJ1 (BJ1-
iPS4). All iPSC clones had typical characteristics of human
pluripotent stem cells indicating successful reprogramming (Fig. 2),
including: a) human embryonic stem cell colony-like morphology,
b) alkaline phosphatase expression and immunoreactivity for
OCT4 (POU5F1), NANOG and Stage-specific embryonic
antigen-4 (SSEA-4) (Fig. 2A), c) expression of endogenous OCT4,
NANOG, and REX1 (Fig. 2B), d) de-methylation of the endogenous
OCT4 promoter (Fig. 2C), and e) normal karyotypes (data not
shown) [29]. In addition, both FXS and control iPSC clones
differentiated into all three germ layers in vitro (Fig. 2D) [30],
including early neural tissue. Importantly, in concordance with the
assessment of a loss of GFP expression from the retroviral vectors,
analysis of transgene expression in the control and Fragile X
syndrome iPSC clones using RT-PCR and primers specific for
transgene cMYC, OCT4/POU5F1, KLF4, SOX2 indicated a
silencing of their expression (Fig. S2). Observation of the growth
rate and the ability to remain undifferentiated in culture over
Table 1. Characteristics of FXS patient-derived and healthy
control fibroblasts selected for reprogramming.
Cell Line ID Source Age at Sampling Clinical Description
BJ1 ATCC 1 day Clinically Unaffected
GM08330 Coriell Institute 63 yrs Clinically Unaffected
GM05848 Coriell Institute 4 yrs Diagnosed FXS
GM05131 Coriell Institute 3 yrs Diagnosed FXS
GM05185 Coriell Institute 26 yrs Diagnosed FXS
doi:10.1371/journal.pone.0026203.t001
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many passages (.20) did not reveal any obvious qualitative
differences between the unaffected control and FXS iPSC lines.
Generation of Both FXS Full Mutation and Unaffected
iPSCs from a Mosaic Culture
We found that the two iPSC clones we generated from the
GM05131 cell line appear to be derived from the two different
fibroblast subpopulations. One iPSC clone had approximately 700
and the other 140 CGG repeats (Fig. 3). These CGG-repeat
lengths are similar to those detected in the heterogeneous input
fibroblasts (Fig. 3A). Characterization of methylation of the FMR1
promoter region showed that, as expected, the iPSC clone 131-
iPS1 (CGG-repeat length of 700) had a mean CpG methylation of
approximately 90%, while clone 131-iPS3 (142 CGG repeats) was
essentially unmethylated (Fig. 3B). FMR1 expression analysis
showed that there were no detectable transcripts from the fully
CpG methylated 131-iPS1 clone, while the premutation 131-iPS3
clone showed increased expression compared to the unaffected
controls (Fig. 3C). The distinctive difference between these two
clones shows that derivation of iPSC resulted in clonal selection of
these two subpopulations from the mosaic population.
Figure 1. Analysis Fragile X Patient Fibroblasts: FMR1 CGG-repeat Length, CpG Methylation, and Expression. (A) Predominant CGG-
repeat size in the FMR1 promoter as determined by Southern blot analysis. (B) Bisulphite pyrosequencing analysis of the FMR1 promoter reported as
relative methylation level at indicated CpG positions (FMR1 promoter CpG site schematic not to scale). (C) FMR1 transcript expression levels as
determined by qRT-PCR shown as fold increase over BJ1 control (ND - non-detectable). (D) Western blot analysis of FMRP protein levels in indicated
fibroblast lines, b-actin is shown as a loading control.
doi:10.1371/journal.pone.0026203.g001
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FMRP protein expression differed in the full- and pre-mutation
iPSC clones (Fig. 3D). The full mutation 131-iPS1 line did not
show detectable FMRP expression, whereas the 131-iPS3
premutation line showed low, but detectable, levels of FMRP.
Thus, the premutation clone 131-iPS3 had a combination of
increased FMR1 mRNA expression and decreased protein
production; this phenomenon has been observed before [26,27],
and the reduced protein-to-mRNA ratio has been attributed to
reduced translational efficiency of the premutation transcript.
Reprogramming Effects on Trinucleotide Repeat Length,
FMR1 Expression and CpG Methylation
While the trinucleotide repeat lengths in the mosaic fibroblast
population appeared to remain similar after reprogramming, in
several cases iPSC lines derived from FXS fibroblast lines had
FMR1 CGG-repeat lengths that were clearly different from the
original fibroblasts (Fig. 3A). The two FXS GM05848-derived
iPSC clones had different predominant CGG-repeat lengths: clone
848-iPS1 had the expected 700 CGG repeats, coinciding closely to
that of the input fibroblasts, but the other clone from this fibroblast
line, 848-iPS3, showed a range of CGG-repeat lengths ranging
from 400–900 repeats (Fig. 3A). This suggests that at some point
during the reprogramming process, or subsequent expansion, the
CGG repeats became unstable in this clone. We detected no
changes in the CpG methylation status of the promoter compared
to the input fibroblasts (Fig. 3B) and there was as no detectable
FMR1 transcript expression (Fig. 3C).
We observed a different type of repeat length change in the
FXS GM05185-derived iPSCs. The fibroblast line contained
approximately 800 CCG repeats as determined by Southern blot
analysis, but after reprogramming the 185-iPS1 line had two
different discrete predominant lengths of approximately 200 and
700 CGG repeats. Since these are male cells, the existence of two
bands from an X-linked gene indicates that this iPSC line
contained two distinctly different subtypes. Promoter CpG
methylation analysis showed a mean of 22% in these cells (Fig.
3B), in contrast to the GM05185 fibroblasts, which were almost
completely methylated in the CpG site in this region. This
methylation content is likely to be due to contributions from the
two populations, one highly methylated and the other relatively
unmethylated. The 200 CGG-repeat length is indicative of the
premutation state, so it would be expected that FMR1 trans-
cription would be increased relative to fully mutated and control
cells. Indeed, the mRNA level in 185-iPS1 cells was several fold
higher than controls (Fig. 3C). These cells also showed a lack of
FMRP protein production, indicating defective translation of the
premutation transcript.
The source of the 200-repeat iPSC subpopulation is not
clear. There was no premutation population detected in the
fibroblast cultures and the fibroblasts had no detectable FMR1
transcript expression. It is possible that the reprogramming
selected for a rare undetectable premutation subpopulation
within the fibroblast culture. Because we also observed changes
in repeat length in the 848-iPS3 FXS iPSC line, it is also possible
that the reprogramming process itself led to CGG-repeat length
shortening.
Aberrant Neural Differentiation from FX iPSCs is
Dependent on CGG Repeat Length and FMR1
Methylation
Since ASDs are neurodevelopmental disorders, we investigated
the effects of FXS mutations on iPSC differentiation along a neural
lineage. Previous reports have been inconsistent about the effects of
FXS on neuronal differentiation; one study [31], reported that in
vitro differentiation of neurospheres derived from post-mortem
human FXS brain and unaffected fetal brain showed differences in
morphology, neurite number and length, and an altered ratio of
Tuj1-positive to glial fibrillary acidic protein (GFAP)-positive cells;
another similar study saw no significant differences in neural
differentiation between FXS and control cells [32].
We compared neural differentiation from clones with high
FMR1 CpG methylation (848-iPS1, 848-iPS3, and 131-iPS1) with
that of unmethylated clones (131-iPS3 and 8330-iPS8). We
generated NESTIN+ and SOX1+ expandable neural progenitor
cells and characterized their FMR1 promoter CpG methylation
status and FMRP expression levels, which were observed to closely
correspond to the iPSC clones from which they were derived (Fig.
4). We then analyzed differentiated iPSC-derived progenitor cells
after withdrawal of mitogenic factors (EGF, bFGF) using
immunocytochemistry for lineage-specific markers Tuj1 (neural)
and GFAP (glial). We found that all of the tested iPSC-derived
progenitor lines could be induced to form neurons and glia (Fig. 5
and Fig. S1). However, there was a notable difference between the
FXS and control cells in the number and length of the processes of
Tuj1-positive cells (Fig. 5 and Fig. S1). The control cells (FMR1
unmethylated, 8330-iPS8 and 131-iPS3) had extensive long and
highly branched processes, while the FXS iPSC-derived cells
(FMR1 methylated; 848-iPS1, 848-iPS3, and 131-iPS1) exhibited
fewer and much shorter processes (Fig. 5 and Fig. S1). The FXS
cells also appeared to be flatter and have only a single process. It is
of interest to note that the two subclones (131-iPS1 and 131-iPS3)
derived from the mosaic donor differed in their neural dif-
ferentiation in spite of their presumed common genetic back-
ground (Fig. 6).
Glial cells also differed in the differentiated cultures (Fig. 6 and
Fig. S1 F–J). The unmethylated control line 8330-iPS8 generated
only a few GFAP-positive cells with long processes, which were
distributed in patches throughout the cultures. One of the FXS
lines, 131-iPS1 was similar to the control (Fig. 6 and Fig. S1 F–J).
In contrast, the cultures derived from the two 848-iPSC FXS lines
(848-iPS1 and 848-iPS3) consistently had a larger number of
GFAP-positive cells with more compact morphology (Fig. 6B and
Fig. S1 G,H,L and M). However, one of the FXS lines, 131-iPS1,
more closely resembled control lines in its GFAP expression (Fig.
6C and Fig. S1 I and N). These observations suggest that glial
phenotypes may be more variable among different FXS patient-
derived iPSC models and that factors other than FMR1 affect glial,
but not neuronal differentiation.
Discussion
Fragile X Syndrome (FXS) is one of a group of genetic diseases
that are caused by pathogenic expansion of a trinucleotide repeat.
Figure 2. Derivation and Characterization of FXS Induced Pluripotent Stem Cells. (A) Alkaline phosphatase enzymatic and pluripotent
marker (OCT4, NANOG and SSEA-4) immunocytochemical analysis of FXS patient-derived iPSC clones. (B) Endogenous OCT4, NANOG and REX1
pluripotency-associated transcript expression as analyzed by RT-PCR in indicated iPSC lines and fibroblasts (NTC - non-template containing control).
(C) Bisulphite pyrosequencing analysis of the endogenous OCT4/POU5F1 promoter in indicated lines (open circles, unmethylated (,50%) CpGs; black
circles, methylated CpGs). (D) Embryoid body pathological evaluation of H&E stained sections (clone 848-iPS1 shown) indicating representative
ectoderm (neural epithelium, left), endoderm (respiratory epithelium, center) and mesoderm (connective tissue, right) germ layers.
doi:10.1371/journal.pone.0026203.g002
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The diseases, including Huntington’s disease and Friedreich’s
ataxia, are characterized by neurological dysfunction, often in
specific regions of the CNS. The trinucleotide repeats disrupt
specific genes in each disease, but very little is known about how
the expansion reaches pathological levels and how the dysfunction
of specific genes leads to neurological disorder. In some cases, such
as Huntington’s disease, the expanded repeat is exonic and causes
the expression of a pathogenic protein [33]. In FXS and
Friedreich’s ataxia [14], the repeat is in a non-coding region of
the gene and the pathogenic expansion results in silencing of the
gene through epigenetic mechanisms. In FXS, the disease is
triggered when there are 200 or more copies of a CGG
trinucleotide repeat in the 59UTR of the FMR1 gene. The
number of repeats predicts the pathology: unaffected individuals
have about 30 repeats, the FMR1 gene promoter is unmethylated,
and the FMRP protein is expressed; full mutation individuals
Figure 3. Effects of iPSC Generation on FMR1 CGG-repeat Length, CpG Methylation and Expression. (A) Predominant CGG-repeat length
in the FMR1 promoter as determined by Southern blot analysis. (B) Pyrosequencing analysis of the FMR1 promoter reported as relative methylation
level at indicated CpG positions (FMR1 promoter CpG site schematic not to scale). (C) FMR1 transcript expression levels as determined by qRT-PCR
shown as fold increase over BJ1 control (ND - non-detectable). (D) Western blot analysis of FMRP protein levels in indicated iPSC lines, b-actin was
used as a loading control.
doi:10.1371/journal.pone.0026203.g003
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(.200 repeats) have fully methylated FMR1 and produce no
protein [10]. Interestingly, the intermediate premutation (ca. 100–
150 copies) has elevated transcription but translation of the FMRP
protein is inefficient [26,27]. Premutation carriers, while having
normal intelligence, demonstrate a range of psychiatric and
behavioral symptoms and are associated with a number of medical
conditions such as Fragile X-associated tremor/ataxia (FXTAS)
and Premature Ovarian Insuffuciency (POI) in response to the
elevated transcription levels of FMR1 [34].
Trinucleotide repeat diseases have been difficult to study
because of limitations in availability of cells and tissues from the
brains of affected individuals. Mouse models of these diseases are
suboptimal because of differences in neural development in mouse
and human. The development of iPSC technology has enabled in
vitro studies of central nervous system cells derived from patients
with genetic neurological disease. However, the value of iPSC
modeling of human disease relies on the assumption that the
resulting iPSC lines contain the same causative elements of the
disease that the input patient cells contained. The data we present
here draw into question this assumption, and show that the iPSCs
derived from FXS individuals do not necessarily faithfully
reproduce the CGG-repeat lengths, CpG methylation status,
and silencing of the FMR1 gene in the fibroblasts of origin. We
also show that differences in neuronal differentiation among FXS
iPSC lines are attributable at least in part by the epigenetic status
of the FMR1 gene promoter.
Existing mouse models with a knock-out of Fmr1 are not
appropriate for investigating questions of repeat stability or the
epigenetic mechanisms of FMR1 silencing as they lack the
expanded trinucleotide repeat. Knock-in mouse models in which
the murine CGG repeat has been replaced with a premutation-
sized CGG repeat from humans were reported to exhibit
moderate repeat instability with both paternal and material
transmission [35,36]. However, in addition to CGG-repeat length,
since the nature of the flanking sequences in combination with the
patterns of interruption of CGG repeats can influence nucleoso-
mal structure and alter CGG repeat instability [37,38], the use of
genetically accurate, human neuronal models will be advantageous
Figure 4. Isolation and Characterization of Expandable Neuronal Progenitor Cells from iPSC Clones. (A) Immunocytochemical analysis
of NESTIN and SOX1 (red, nuclei DNA staining overlaid in blue) expression in expanded neural cells from indicated iPSC lines expanded in the
presence of mitogens EGF and bFGF. (B) Bisulphite pyrosequencing analysis of the FMR1 promoter reported as relative methylation level at indicated
CpG positions in indicated neural differentiated iPSC lines (FMR1 promoter CpG site schematic not to scale). (C) Western blot analysis of FMRP protein
levels in indicated neural differentiated iPSC lines, b-actin is shown as a loading control.
doi:10.1371/journal.pone.0026203.g004
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to investigate the molecular mechanisms of trinucleotide repeat
instability and epigenetic regulation.
In one case, we discovered that a patient fibroblast cell line,
GM05131, is a heterogeneous mixture of normal and full FXS
mutation cells. Reprogramming of these fibroblasts resulted in two
iPSC clones, one with the full FXS mutation (ca. 700 CGG
repeats) and the other with premutation repeat length (ca. 142
repeats). As expected, the full mutation cells produced no FMR1
transcript and the premutation clone had above-normal FMR1
transcription levels but very low translation of the FMRP protein.
These two clones are presumably otherwise genetically matched,
which will be valuable for comparison of the effects of the full- and
premutation in the absence of potentially confounding background
genetics. Interestingly, the CGG-repeat lengths in the iPSCs
appeared to be slightly shorter than those of the fibroblasts (700 vs.
800; 142 vs. 166); in light of the similar changes that appeared
upon reprogramming of the other fibroblast lines (see below), it
seems possible that the reprogramming process may lead to
instability of trinucleotide repeat lengths.
A second FXS line, GM05848 (ca. 700 CGG repeats), gave rise
to an iPSC clone that apparently possessed multiple trinucleotide
repeat lengths ranging from 400 to 900. And the third FXS line
reprogrammed (GM05185) had a predominant trinucleotide
repeat of 800, but produced a heterogeneous iPSC line (185-
iPS1) with discrete repeat lengths (200 and 700). There was no
apparent heterogeneity in the input fibroblasts, as evidenced by
lack of FMR1 transcript detected, even after extensive qRT-PCR
(40–45 rounds). The full mutation iPSC clones (848-iPS1 and -
iPS3) showed no detectable FMR1 expression, but the 185-iPS1
clone, with a de novo premutation subpopulation present, expressed
the high levels of FMR1 transcript typical of premutation cells.
These data suggest that reprogramming of full mutation FXS
fibroblasts results in changes, generally shortening, of the repeat
length in the resulting iPSC clones. A varied population of repeat
lengths in one isolated iPSC clone (848-iPS3) suggests that change
in CGG-repeat length is a dynamic process that occurs because of
instability of the CGG repeat initiated during reprogramming. An
earlier study reported that full mutation human FMR1 alleles
stably maintained in patient fibroblasts and murine A9 somatic
hybrid cells contracted upon transfer to pluripotent embryocarci-
noma (PC13) cells due to instability upon passage [39]. Repeat
instability is also suggested by the variable repeat lengths observed
in a human embryonic stem cell line derived from a FXS-affected
embryo, which showed repeat length heterogeneity from 200 to
more than 1,000 triplet CGG repeats in the same isolated clone
[19].
This is the first report of trinucleotide repeat length change in
FXS iPSCs. A previous analysis of FXS iPSCs did not report
trinucleotide repeat length changes [40]. However, changes in
repeat length with reprogramming has been reported for another
trinucleotide repeat disease, Friedrich’s ataxia [41]; in that case, in
iPSCs there was an expansion of an intronic GAA repeat that
Figure 5. Aberrant Neural Differentiation of FXS iPSC-derived Neuronal Progenitors. Immunocytochemical analysis of Tuj1 expression
(green) in neuronal progenitor cells differentiated upon mitogen removal of (A) FMRP+ control line 8330-8 and (B) FMRP- FXS line 848-3, overlaid with
nuclei DNA staining (blue) (see Figure S1 for additional images). (C) Quantification of neurite process length in indicated iPSC-NP lines. Two wells (6-
well plate) were imaged, 9 images per well (n = 18 images per sample). P-values as indicated *1.5e-13, **1.1e-10, ***3.1e-13, ****1.4e-4.
doi:10.1371/journal.pone.0026203.g005
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silences the FXN gene on chromosome 9. That report and the
current study suggest that reprogramming may destabilize repeats
in certain trinucleotide repeat diseases. Further investigation of this
phenomenon may help in understanding the basis of transgenera-
tional instability of pathological trinucleotide repeat sequences in
many neurodevelopmental diseases.
The impact of repeat instability on iPSC in vitro models of FXS
could be considerable if the iPSC repeat length is not determined.
We found that in general the actual repeat length in the iPSCs
predicted the methylation status and expression levels of FMRP
transcripts and proteins, and therefore the disease state, regardless
of the status of the input fibroblasts. If the changes in repeat length
are truly dynamic, researchers may find unexpected phenotypes in
iPSC derivatives if they do not monitor the repeat length in the cells.
Two previous reports have investigated FMR1 expression in
human pluripotent cells, with conflicting results: one study used FXS
human embryonic stem cells (hESCs) [19] and the second studied
FXS iPSCs [40]. The first report indicated that the FMR1 gene was
expressed in the FXS-hESCs, despite the cells having full mutation
status, and was repressed only after differentiation [19]. The second
study reported that FMR1 expression was repressed in both full
mutation undifferentiated FXS-hESCs and FXS patient-derived
iPSCs (from the GM05848 line) [40]. Our results support the report
on FXS iPSCs; we observed promoter CpG methylation and FMR1
repression in GM05848-derived iPSCs as well as in all other iPSC
clones that contained only full mutation alleles. We also character-
ized neuronal differentiation in several FXS iPSC lines, showing for
the first time that the CpG methylation state of the FMR1 gene in
iPSCs persists during neuronal differentiation, an observation that is
critical for efforts to use iPSC-derived cells to model FXS.
We observed FXS-associated morphological differences in
iPSC-derived neurons, with FXS cells having fewer and shorter
neurites than controls. Similar neuronal morphology has been
reported in FMR1 knock-out mouse models [42,43] and post-
mortem fetal FXS brain tissue [31,44]. The morphological
differences correlated with FMR1 promoter CpG methylation
status and expression of FMR1, and occurred in multiple iPSC
lines from different source fibroblasts. We also observed variations
in glial differentiation as assessed by GFAP immunostaining,
although these phenotypes were not strictly linked to FMR1
methylation status. There have been previous reports of
differences in glial/neuronal ratios in FXS-derived cell cultures.
Adult neural stem cells from the dentate gyrus of Fmr1 knockout
mice showed increased glial differentiation as compared to
controls [43]. Observations using human neural tissue differ and
are possibly brain region-specific; neurospheres derived from FXS
hippocampal tissue showed reduced glial differentiation [31,44],
whereas cortex-derived cells were unaffected [32].
Overall, our results suggest an important role for FMRP early in
human neurodevelopment. In this context, future studies will be
aimed toward understanding the molecular basis of the observed
phenotypes and exploring the consequence of a loss of FMRP on
signaling and synaptic function in FXS–derived neuronal cells.
Having identified a robust, morphological phenotype upon neural
differentiation of FXS iPSCs provides an opportunity for the
characterization of existing pharmacological agents and to
Figure 6. Rescue of Aberrant Neural Differentiation of FXS iPSC-derived Neuronal Progenitors by FMRP Expression in Premutation
Clones. Immunocytochemical analysis of expanded neuronal progenitor cells differentiated upon mitogen removal of FMRP+ control line 8330-8 (A)
and FMRP- FXS lines 848-3 and 131-1 (B and C) and FMRP+ FXS line 131-3 (D), overlay of Tuj1 staining (green), GFAP (red) and nuclei DNA staining
(blue) (see Figure S1 for additional images).
doi:10.1371/journal.pone.0026203.g006
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potentially discover novel therapeutics that can reverse disease-
associated phenotypes in FXS and other ASDs sharing common
pathophysiology.
Supporting Information
Figure S1 Analysis of Tuj1 and GFAP Expression Upon
Post-mitotic Neural Differentiation. Immunocytochemical
analysis of expanded neural cells differentiated upon mitogen
removal. (A to E) Tuj1 staining (100X) indicated in green. F to J)
GFAP staining (100x) indicated in red. (K to O) Tuj1(green) and
GFAP (red) overlay (400X). In all images, nuclei DNA co-staining
is indicated in blue.
(TIF)
Figure S2 RT-PCR Verification of Reprogramming
Transgene Silencing of GFP-minus iPSC Clones. Trans-
gene specific RT-PCR demonstrates silencing of retroviral–specific
reprogramming genes (OCT4/POU5F1, SOX2, KLF4 and cMYC) in
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